Literature DB >> 15133367

Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins.

Alan Bulava1, Ludek Slavík, Martin Fiala, Petr Heinc, Marcela Skvarilova, Jan Lukl, Vera Krcová, Karel Indrák.   

Abstract

AIMS: To determine the systemic thrombogenic effect of radiofrequency catheter isolation of the pulmonary veins (PVI) in the treatment of atrial fibrillation. METHODS AND
RESULTS: We studied endothelial damage marker (von Willebrand factor [vWf]), fibrinolysis markers (tissue plasminogen activator [t-PA], plasminogen activator inhibitor-1 [PAI-1]) and coagulation activation markers (D-dimer [DD]) in 30 patients (pts) undergoing PVI. Heparin was administered continuously after double transseptal puncture in all pts. Concentrations of vWf and t-PA were significantly increased after accomplishing PVI compared to the baseline values, and elevated levels persisted 24 hours later ( p < 0.01). PAI-1 levels decreased following PVI compared to the baseline levels ( p = 0.02). PAI-1 levels normalized 24 hours after the procedure. DD increased continuously during the procedure with the peak following PVI ( p < 0.01). Higher DD concentrations persisted 24 hours later ( p = 0.02). In a multivariate analysis, total procedure time correlated significantly with the peak vWf and DD concentrations, while total RF energy dose correlated only with peak vWf ( r = 0.82). Time to heparin administration correlated with DD levels prior to the first RF pulse ( r = 0.83, p < 0.01) as well as after PVI ( r = 0.75, p < 0.01). A group of patients heparinized within the first hour of the PVI procedure had normal preablation DD levels and significantly mitigated DD levels following PVI compared to the group of patients heparinized later ( p < 0.01).
CONCLUSIONS: Pulmonary vein ablations cause an increased systemic procoagulant state as reflected by fibrin turnover, fibrinolysis activation and endothelial perturbation. The activation of the coagulation cascade could be decreased by early heparin administration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133367     DOI: 10.1023/B:JICE.0000026924.96281.be

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  35 in total

Review 1.  Receptors for plasminogen and t-PA: an update.

Authors:  A Redlitz; E F Plow
Journal:  Baillieres Clin Haematol       Date:  1995-06

Review 2.  Of mice and men. The function of plasminogen activator inhibitors (PAIs) in vivo.

Authors:  D T Eitzman; D Ginsburg
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

3.  Pretreatment with aspirin and ticlopidine confers lower thrombogenic potential of radiofrequency catheter ablation.

Authors:  A S Manolis; V Vassilikos; T N Maounis; L Psarros; H Melita-Manolis; D Papatheou; A Haliassos; V Christopoulou-Cokkinou; D V Cokkinos
Journal:  Am J Cardiol       Date:  1997-02-15       Impact factor: 2.778

4.  Thrombogenicity of radiofrequency lesions: results with serial D-dimer determinations.

Authors:  A S Manolis; H Melita-Manolis; V Vassilikos; T Maounis; J Chiladakis; V Christopoulou-Cokkinou; D V Cokkinos
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

Review 5.  Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.

Authors:  T K Nordt; K Peter; J Ruef; W Kübler; C Bode
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

6.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

7.  Histopathology of canine hearts subjected to catheter ablation using radiofrequency energy.

Authors:  K Tanno; Y Kobayashi; K Kurano; S Kikushima; T Yazawa; T Baba; S Inoue; H Mukai; T Katagiri
Journal:  Jpn Circ J       Date:  1994-02

Review 8.  Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers.

Authors:  M D Boisclair; H Philippou; D A Lane
Journal:  Blood Coagul Fibrinolysis       Date:  1993-12       Impact factor: 1.276

Review 9.  Radio-frequency catheter ablation of cardiac arrhythmias: appraisal of an evolving therapeutic modality.

Authors:  S K Huang
Journal:  Am Heart J       Date:  1989-12       Impact factor: 4.749

10.  Embolic complications associated with radiofrequency catheter ablation. Atakr Investigator Group.

Authors:  M R Epstein; L D Knapp; M Martindill; J A Lulu; J K Triedman; H Calkins; S K Huang; E P Walsh; J P Saul
Journal:  Am J Cardiol       Date:  1996-03-15       Impact factor: 2.778

View more
  9 in total

Review 1.  Cerebral Embolization During AF Ablation -Pathophysiology, Prevention and Management.

Authors:  Nasir Shariff; Nagesh Antha; Manish Roy; Hari Joshi; Vadim Levin
Journal:  J Atr Fibrillation       Date:  2013-04-06

2.  Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation.

Authors:  Charles J Bruce; Paul A Friedman; Om Narayan; Thomas M Munger; Stephen C Hammill; Douglas L Packer; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2008-06-21       Impact factor: 1.900

Review 3.  [Biomarkers and atrial fibrillation : Prediction of recurrences and thromboembolic events after rhythm control management].

Authors:  Jelena Kornej; Katja Schumacher; Daniela Husser; Gerhard Hindricks
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

4.  A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.

Authors:  Akinori Sairaku; Yukihiko Yoshida; Monami Ando; Haruo Hirayama; Yukiko Nakano; Yasuki Kihara
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

5.  Periprocedural coagulability in patients undergoing ablation of atrial fibrillation: lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging.

Authors:  Akinori Sairaku; Yukihiko Yoshida; Haruo Hirayama; Yukiko Nakano; Yasuki Kihara
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

6.  Atrial Fibrillation Ablation without Interruption of Anticoagulation.

Authors:  Pasquale Santangeli; Luigi Di Biase; Javier E Sanchez; Rodney Horton; Andrea Natale
Journal:  Cardiol Res Pract       Date:  2011-04-26       Impact factor: 1.866

7.  Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von Willebrand factor and IL-6 in the peripheral and cardiac circulation.

Authors:  Jelena Kornej; Borislav Dinov; Andrew D Blann; Sascha Rolf; Arash Arya; Josephine Schmidl; Daniela Husser; Gerhard Hindricks; Andreas Bollmann; Gregory Y H Lip
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

8.  Prognostic implications and procoagulant activity of phosphatidylserine exposure of blood cells and microparticles in patients with atrial fibrillation treated with pulmonary vein isolation.

Authors:  Huan Meng; Junjie Kou; Ruishuang Ma; Wenbo Ding; Yan Kou; Muhua Cao; Zengxiang Dong; Yayan Bi; Hemant S Thatte; Jialan Shi
Journal:  Mol Med Rep       Date:  2017-10-11       Impact factor: 2.952

9.  Intracardiac Fibrinolysis and Endothelium Activation Related to Atrial Fibrillation Ablation with Different Techniques.

Authors:  Orsolya Hajas; Zsuzsa Bagoly; Noémi K Tóth; Réka Urbancsek; Alexandra Kiss; Kitti B Kovács; Ferenc Sarkady; Attila Nagy; Anna V Oláh; László Nagy; Marcell Clemens; László Csiba; Zoltán Csanádi
Journal:  Cardiol Res Pract       Date:  2020-02-12       Impact factor: 1.866

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.